{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:13:39Z","timestamp":1788351219287,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Patients with clonal cytopenia of undetermined significance (CCUS) are at increased risk of developing myeloid neoplasia (MN). We evaluated whether a simple flow cytometry immunophenotyping (FCIP) assay could differentiate the risk of development of MN in patients with CCUS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Bone marrow aspirates were assessed by FCIP panel in a cohort of 80 patients identified as having CCUS based on next-generation sequencing or cytogenetics from March 2015 to May 2020, with available samples. Flow cytometric assay included CD13\/HLA-DR expression pattern on CD34-positive myeloblasts; CD13\/CD16 pattern on maturing granulocytic precursors; and aberrant expression of CD2, CD7, or CD56 on CD34-positive myeloblasts. Relevant demographic, comorbidity, and clinical and laboratory data, including the type and extent of genetic abnormalities, were extracted from the electronic health record.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 17 (21%) patients with CCUS developed MN over the follow-up period (median survival follow-up, 28 months [95% confidence interval, 19-31]). Flow cytometry immunophenotyping abnormalities, including the aberrant pattern of CD13\/HLA-DR expression, as detected at the time of the diagnosis of CCUS, were significantly associated with risk of developing MN (hazard ratio, 2.97; P = .006). Additional FCIP parameters associated with the development of MN included abnormal expression of CD7 on myeloblasts and the presence vs absence of any FCIP abnormality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A simple FCIP approach that includes assessment of CD13\/HLA-DR pattern on CD34-positive myeloblasts can be useful in identifying patients with CCUS at higher risk of developing MN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqac083","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T10:58:51Z","timestamp":1659956331000},"page":"530-536","source":"Crossref","is-referenced-by-count":7,"title":["Abnormal CD13\/HLA-DR Expression Pattern on Myeloblasts Predicts Development of Myeloid Neoplasia in Patients With Clonal Cytopenia of Undetermined Significance"],"prefix":"10.1093","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"first","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Nanaa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Geyer","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Timm","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Azouz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hengel","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reberg","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6116-8163","authenticated-orcid":false,"given":"Rong","family":"He","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Viswanatha","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad E","family":"Salama","sequence":"additional","affiliation":[{"name":"Sonic Healthcare USA , Austin, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Otteson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T","family":"Greipp","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"},{"name":"Division of Laboratory Genetics and Genomics, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B","family":"Alkhateeb","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong L","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"2022100608585655700_CIT0001","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours","author":"Swerdlow","year":"2017","edition":"4"},{"key":"2022100608585655700_CIT0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood."},{"key":"2022100608585655700_CIT0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk Res."},{"key":"2022100608585655700_CIT0004","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood."},{"key":"2022100608585655700_CIT0005","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood."},{"key":"2022100608585655700_CIT0006","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget."},{"key":"2022100608585655700_CIT0007","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2014.191","article-title":"Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes\u2014proposal from the International\/European LeukemiaNet Working Group for Flow Cytometry in MDS","volume":"28","author":"Porwit","year":"2014","journal-title":"Leukemia."},{"key":"2022100608585655700_CIT0008","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2012.30","article-title":"Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group","volume":"26","author":"Westers","year":"2012","journal-title":"Leukemia."},{"key":"2022100608585655700_CIT0009","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/cyto.b.21842","article-title":"The diagnostic and prognostic role of flow cytometry in idiopathic and clonal cytopenia of undetermined significance (ICUS\/CCUS): a single-center analysis of 79 patients","volume":"98","author":"Dimopoulos","year":"2020","journal-title":"Cytometry B Clin Cytom."},{"key":"2022100608585655700_CIT0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1309\/AJCP73QSLLYDEGXK","article-title":"Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms","volume":"142","author":"Jevremovic","year":"2014","journal-title":"Am J Clin Pathol."},{"key":"2022100608585655700_CIT0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cll.2017.07.006","article-title":"Flow cytometric assessment of chronic myeloid neoplasms","volume":"37","author":"Shi","year":"2017","journal-title":"Clin Lab Med."},{"key":"2022100608585655700_CIT0012","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41379-019-0359-9","article-title":"Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis [published correction appears in Mod Pathol. 2020;33:514]","volume":"33","author":"He","year":"2020","journal-title":"Mod Pathol."},{"key":"2022100608585655700_CIT0013","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.12994","article-title":"High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes","volume":"167","author":"Alhan","year":"2014","journal-title":"Br J Haematol."},{"key":"2022100608585655700_CIT0014","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2015.295","article-title":"The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system","volume":"30","author":"Alhan","year":"2016","journal-title":"Leukemia."},{"key":"2022100608585655700_CIT0015","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2009.008532","article-title":"Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study","volume":"94","author":"Ogata","year":"2009","journal-title":"Haematologica."},{"key":"2022100608585655700_CIT0016","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Gall\u00ec","year":"2021","journal-title":"Blood."},{"key":"2022100608585655700_CIT0017","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia."},{"key":"2022100608585655700_CIT0018","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2016.147843","article-title":"Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes","volume":"102","author":"Cremers","year":"2017","journal-title":"Haematologica."},{"key":"2022100608585655700_CIT0019","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1038\/leu.2013.178","article-title":"Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes","volume":"27","author":"Mathis","year":"2013","journal-title":"Leukemia."},{"key":"2022100608585655700_CIT0020","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2016.147835","article-title":"Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes: a report from the IMDSFlow Working Group","volume":"102","author":"Westers","year":"2017","journal-title":"Haematologica."},{"key":"2022100608585655700_CIT0021","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood."},{"key":"2022100608585655700_CIT0022","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/bloodadvances.2019001157","article-title":"Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation","volume":"4","author":"Soerensen","year":"2020","journal-title":"Blood Adv."},{"key":"2022100608585655700_CIT0023","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/cyto.a.24360","article-title":"Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes","volume":"99","author":"Duetz","year":"2021","journal-title":"Cytometry A."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/158\/4\/530\/46333433\/aqac083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/158\/4\/530\/46333433\/aqac083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:49:13Z","timestamp":1665060553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/158\/4\/530\/6658211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,8]]},"published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqac083","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,8]]}}}